October 02, 2013
1 min read

NICE final appraisal recommends funding Iluvien for pseudophakic DME patients

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The United Kingdom’s National Institute for Health and Care Excellence, or NICE, has issued a final appraisal determination calling for funding of Iluvien for the treatment of pseudophakic eyes in patients with chronic diabetic macular edema considered insufficiently responsive to available therapies, according to a news release.

The determination takes into account Alimera Sciences’ patient access scheme, which a NICE appraisal committee found in June met the necessary cost-effectiveness threshold. The final appraisal reverses NICE’s guidance from January.

The U.K., Austria, France, Portugal, Spain and Germany have granted national licenses for Iluvien (sustained-release fluocinolone acetonide intravitreal implant) after Alimera successfully completed the Decentralized Procedure. Marketing approval is pending in Italy, the release said.

The treatment has not been approved by the U.S. Food and Drug Administration.